Atossa Therapeutics Inc (NASDAQ:ATOS) announced it will present data from the 40mg pharmacokinetic run-in cohort of its ongoing Phase 2 EVANGELINE study at the American Association for Cancer Research Annual Meeting being held in San Diego, California, from April 5 to 10.
The EVANGELINE study is evaluating Atossa’s lead asset (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with estrogen receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.
“We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting,” Atossa CEO Dr. Steven Quay said in a statement.
He noted that while neoadjuvant therapy is effective and widely used across many cancer types, the current treatment options for premenopausal women diagnosed with ER+ breast cancer are sub-optimal.
“An effective and tolerable neoadjuvant therapy would transform the treatment approach in this setting, making surgery more effective and reducing the likelihood that the cancer will recur,” Dr. Quay said.
“There is growing excitement and understanding across the breast cancer community that (Z)-endoxifen, if shown to be safe and effective, would be a game changer for premenopausal women.”
Atossa is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.